Evidence map›Paper›PMID 33770141›Full record

ArticlePLoS pathogens2021

Host cystathionine-γ lyase derived hydrogen sulfide protects against Pseudomonas aeruginosa sepsis.

Georgios Renieris, Dionysia-Eirini Droggiti, Konstantina Katrini, Panagiotis Koufargyris, Theologia Gkavogianni, Eleni Karakike, Nikolaos Antonakos, Georgia Damoraki, Athanasios Karageorgos, Labros Sabracos and 10 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Hydrogen Sulfide and Substance P Levels in Patients withInternational journal of molecular sciences · 2022
    Article
  8. HBiomolecules · 2022
    Review
  9. Gases in Sepsis: Novel Mediators and Therapeutic Targets.International journal of molecular sciences · 2022
    Review
  10. The HFrontiers in immunology · 2022
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 5 countries.

Georgios Renieris4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.ORCID 0000-0002-2985-0901
Dionysia-Eirini Droggiti4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Konstantina Katrini4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Panagiotis Koufargyris4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.ORCID 0000-0001-7800-3306
Theologia Gkavogianni4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Eleni Karakike4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Nikolaos Antonakos4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.ORCID 0000-0002-7552-5878
Georgia Damoraki4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Athanasios Karageorgos4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Labros Sabracos4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Antonia KatsoudaCenter of Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Elisa JenthoDepartment of Anesthesiology and Intensive Care, Jena University Hospital, Jena, Germany.ORCID 0000-0002-4790-7860
Sebastian WeisDepartment of Anesthesiology and Intensive Care, Jena University Hospital, Jena, Germany.
Rui WangDepartment of Biology, York University, Toronto, Canada.
Michael BauerDepartment of Anesthesiology and Intensive Care, Jena University Hospital, Jena, Germany.ORCID 0000-0002-1521-3514
Csaba SzaboDepartment of Anaesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.ORCID 0000-0003-3110-4235
Kalliopi Platoni2nd Department of Radiology, National and Kapodistrian University of Athens, Medical School, Athens, Greece.ORCID 0000-0003-2977-7895
Vasilios Kouloulias2nd Department of Radiology, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Andreas PapapetropoulosCenter of Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.ORCID 0000-0002-4253-5930
Evangelos J Giamarellos-Bourboulis4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.ORCID 0000-0003-4713-3911
National and Kapodistrian University of Athens · GRJena University Hospital · DEAcademy of Athens · GRUniversity of Fribourg · CHYork University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydrogen sulfide (H2S) has recently been recognized as a novel gaseous transmitter with several anti-inflammatory properties. The role of host- derived H2S in infections by Pseudomonas aeruginosa was investigated in clinical and mouse models. H2S concentrations and survival was assessed in septic patients with lung infection. Animal experiments using a model of severe systemic multidrug-resistant P. aeruginosa infection were performed using mice with a constitutive knock-out of cystathionine-γ lyase (Cse) gene (Cse-/-) and wild-type mice with a physiological expression (Cse+/+). Experiments were repeated in mice after a) treatment with cyclophosphamide; b) bone marrow transplantation (BMT) from a Cse+/+ donor; c) treatment with H2S synthesis inhibitor aminooxyacetic acid (ΑΟΑΑ) or propargylglycine (PAG) and d) H2S donor sodium thiosulfate (STS) or GYY3147. Bacterial loads and myeloperoxidase activity were measured in tissue samples. The expression of quorum sensing genes (QS) was determined in vivo and in vitro. Cytokine concentration was measured in serum and incubated splenocytes. Patients survivors at day 28 had significantly higher serum H2S compared to non-survivors. A cut- off point of 5.3 μΜ discriminated survivors with sensitivity 92.3%. Mortality after 28 days was 30.9% and 93.7% in patients with H2S higher and less than 5.3 μΜ (p = 7 x 10-6). In mice expression of Cse and application of STS afforded protection against infection with multidrug-resistant P. aeruginosa. Cyclophosphamide pretreatment eliminated the survival benefit of Cse+/+ mice, whereas BMT increased the survival of Cse-/- mice. Cse-/- mice had increased pathogen loads compared to Cse+/+ mice. Phagocytic activity of leukocytes from Cse-/- mice was reduced but was restored after H2S supplementation. An H2S dependent down- regulation of quorum sensing genes of P.aeruginosa could be demonstrated in vivo and in vitro. Endogenous H2S is a potential independent parameter correlating with the outcome of P. aeruginosa. H2S provides resistance to infection by MDR bacterial pathogens.

Indexed as

AnimalsCystathionine gamma-LyaseHumansHydrogen SulfideMiceMice, KnockoutPseudomonas aeruginosaPseudomonas InfectionsSepsisCystathionine gamma-LyaseHydrogen Sulfide

Identifiers

PMID33770141
PMCPMC8051778
OpenAlexW3136680349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.